$Viridian(VRDN)$
- Subcutaneous VRDN-003 topline data readout accelerated to Q1 2026 for REVEAL-1 and narrowed to Q2 2026 for REVEAL-2 for active and chronic TED, respectively; each study exceeded its enrollment target due to strong patient demand -
REVEAL-1 and REVEAL-2 enrolled 132 and 204 patients, respectively, exceeding their target enrollments of 117 and 195 patients, driven by strong patient demand.
牛逼啊，入组不仅加速完成，还多入组了二十五个患者，做一下慈善喽？
有钱了就是底气不一样
strong demand 哪里来的，安进你特么要不要反思